Table 3.
5 Year cumulative probability (95% CI) | Log-rank test chi-square (P value) | HR* (95% CI) | ||
---|---|---|---|---|
Below median | Above median | |||
CD3+ IELs | ||||
Survival | ||||
Stage | ||||
II | 0.77 (0.60–0.95) | 0.87 (0.76–0.99) | 1.04 (0.3) | 0.50 (0.13–1.94) |
III | 0.39 (0.21–0.57) | 0.70 (0.49–0.90) | 4.79 (0.03) | 0.37 (0.14–0.93) |
Overall | 0.55 (0.42–0.69) | 0.80 (0.70–0.91) | 8.22 (0.004) | 0.40 (0.19–0.85) |
Relapse | ||||
Stage | ||||
II | 0.77 (0.60–0.95) | 0.91 (0.80–1.00) | 1.73 (0.2) | 0.40 (0.09–1.76) |
III | 0.42 (0.22–0.61) | 0.65 (0.44–0.86) | 2.96 (0.09) | 0.45 (0.18–1.11) |
Overall | 0.58 (0.44–0.72) | 0.80 (0.70–0.91) | 6.48 (0.01) | 0.42 (0.19–0.92) |
CD8+ IELs | ||||
Survival | ||||
Stage | ||||
II | 0.64 (0.44–0.84) | 0.94 (0.91–1.00) | 8.07 (0.005) | 0.14 (0.03–0.65) |
III | 0.44 (0.26–0.62) | 0.63 (0.42–0.85) | 2.10 (0.1) | 0.50 (0.20–1.22) |
Overall | 0.52 (0.39–0.66) | 0.82 (0.72–0.93) | 11.16 (0.0008) | 0.33 (0.15–0.73) |
Relapse | ||||
Stage | ||||
II | 0.68 (0.48–0.88) | 0.94 (0.86–1.00) | 6.52 (0.01) | 0.17 (0.04–0.83) |
III | 0.42 (0.23–0.62) | 0.64 (0.43–0.86) | 1.71 (0.2) | 0.47 (0.19–1.17) |
Overall | 0.54 (0.40–0.68) | 0.83 (0.73–0.93) | 9.55 (0.002) | 0.35 (0.16–0.78) |
GrB+ IELs | ||||
Survival | ||||
Stage | ||||
II | 0.64 (0.45–0.83) | 0.96 (0.90–1.00) | 9.48 (0.002) | 0.07 (0.01–0.53) |
III | 0.29 (0.12–0.46) | 0.72 (0.54–0.90) | 7.52 (0.006) | 0.32 (0.14–0.77) |
Overall | 0.46 (0.32–0.59) | 0.85 (0.76–0.95) | 17.48 (0.0001) | 0.23 (0.10–0.50) |
Relapse | ||||
Stage | ||||
II | 0.64 (0.44–0.83) | 1.00 (1.00–1.00) | 12.73 (0.0004) | † |
III | 0.28 (0.10–0.46) | 0.72 (0.54–0.89) | 7.12 (0.008) | 0.33 (0.14–0.79) |
Overall | 0.46 (0.32–0.60) | 0.87 (0.78–0.96) | 18.71 (0.0001) | 0.20 (0.09–0.46) |
*Estimates from separate proportional hazard regression models including terms for sex, age, and stage as appropriate. Reference category was represented by cases below the median value.
†No events.